Technology ID

An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder

Lead Inventor
Roche, Katherine (National Institute of Neurological Disorders and Stroke)
Dias da Mota Vieira, Marta (National Institute of Neurological Disorders and Stroke)
Badger, John (National Institute of Neurological Disorders and Stroke)
Research Materials
Therapeutic Areas
Research Products
Lead IC
This technology relates to the generation and use of an antibody that recognizes the S1459 phosphorylated site of the GRIN2A gene, which encodes the GluN2A subunit of the NMDA receptor. This gene is widely accepted as an epilepsy-causative gene and has been implicated in autism spectrum disorder (ASD). The S1459 phosphorylation site was selected based on an identified mutation in an epilepsy patient. This antibody can be used to specifically visualize the localization of the phosphorylated version of the GRIN2A protein product in the brain.
Commercial Applications
This GRIN2A antibody could potentially be used to visualize phosphorylation of this site in the brain.

Competitive Advantages
There are no other antibodies on the market that detect this specific phosphorylation site of the GRIN2A gene, GluN2A-S1459.
Licensing Contact: